ClinicalTrials.gov record
Completed No phase listed Observational

Long-Term Follow-up Safety of Clonidine Micropellets

ClinicalTrials.gov ID: NCT03776318

Public ClinicalTrials.gov record NCT03776318. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 5:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Follow-up Study to Evaluate the Long-Term Safety of Clonidine Micropellets for the Treatment of Pain Associated With Lumbosacral Radiculopathy in Adults

Study identification

NCT ID
NCT03776318
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Sollis Therapeutics, Inc.
Industry
Enrollment
100 participants

Conditions and interventions

Interventions

  • Long-Term Safety Follow-up Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 14, 2018
Primary completion
Jan 21, 2021
Completion
May 30, 2021
Last update posted
Oct 5, 2023

2018 – 2021

United States locations

U.S. sites
25
U.S. states
19
U.S. cities
24
Facility City State ZIP Site status
Sollis Clinical Study Site 36 Mobile Alabama 36605
Sollis Clinical Study Site 44 Phoenix Arizona 85053
Sollis Clinical Study Site 40 Tucson Arizona 85724
Sollis Clinical Study Site 49 Rancho Mirage California 92270
Sollis Clinical Study Site 30 Washington D.C. District of Columbia 22205
Sollis Clinical Study Site 35 Fort Lauderdale Florida 33316
Sollis Clinical Study Site 38 Miami Florida 33135
Sollis Clinical Study Site 12 Bloomington Illinois 61704
Sollis Clinical Study Site 13 Chicago Illinois 60657
Sollis Clinical Study Site 14 Kansas City Kansas 66160
Sollis Clinical Study Site 37 Overland Park Kansas 66210
Sollis Clinical Study Site 10 Edgewood Kentucky 41017
Sollis Clinical Study Site 15 Brookline Massachusetts 02445
Sollis Clinical Study Site 17 Shrewsbury New Jersey 07702
Sollis Clinical Study Site 31 Rochester New York 14618
Sollis Clinical Study Site 18 Winston-Salem North Carolina 27103
Sollis Clinical Study Site 21 Cleveland Ohio 44106
Sollis Clinical Study Site 33 Cleveland Ohio 44195
Sollis Clinical Study Site 19 Edmond Oklahoma 73013
Sollis Clinical Study Site 46 Eugene Oregon 97401
Sollis Clinical Study Site 42 Dallas Texas 75240
Sollis Clinical Study Site 34 Houston Texas 77004
Sollis Clinical Study Site 47 Salt Lake City Utah 84107
Sollis Clinical Study Site 23 Morgantown West Virginia 26506
Sollis Clinical Study Site 27 Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03776318, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 5, 2023 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03776318 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →